ArticleJournal of the National Cancer Institute2010
Improved estimates of cancer-specific survival rates from population-based data.
Article in Journal of the National Cancer Institute, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 243 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
243 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.Frontiers in pharmacology · 2023Pooled it
- Immune-related conditions and cancer-specific mortality among older adults with cancer in the United States.International journal of cancer · 2022Pooled it
- Impact of Socioeconomic Status on Early Gastric Cancer Outcomes and Treatment Disparity: a SEER analysis.Journal of gastrointestinal cancer · 2026Article
- Cancer Patients Mortality From Other Causes: A European Population-Based Study.Cancer medicine · 2026Article
- Annual hazard rates for early-stage endometrial carcinoma after postoperative radiotherapy under FIGO 2023 staging system: results from a population-based single-center cohort study.Journal of gynecologic oncology · 2026Article
- Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001-2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Sex-specific differences in patients with differentiated thyroid carcinoma and their possible impact on survival.European journal of nuclear medicine and molecular imaging · 2026Article
- Stage-dependent prognostic impact of age in colorectal cancer: A population-based SEER analysis.Scientific reports · 2026Article
- Industrial air pollution and lung and bronchus cancer survival in New Mexico, USA.Cancer causes & control : CCC · 2026Article
- Comparison of survival outcomes between kidney transplant and dialysis in patients with previous cancer.Chinese medical journal · 2026Observational
- Long-Term Survival Disparities by Race and Ethnicity Among Cancer Survivors in United States.Cancer medicine · 2026Article
- Associations of fine particulate matter pollution components with overall, prostate cancer, and cardiovascular disease mortality in men with prostate cancer: A cohort study.Environmental research · 2026Article
- Outcomes Among Patients With Colon Cancer Living in Neighborhoods With Persistent Poverty.JAMA network open · 2026Article
- Hysterectomy Status and Outcomes in Patients With Grade 1, Stage IA Endometrioid Adenocarcinoma.O&G open · 2025Article
- Travel Time to Treating Facility and Mortality in Men With Prostate Cancer.JAMA network open · 2025Article
- Article
- The impact of cancer survivors' extra risk of noncancer mortality on net survival estimation.American journal of epidemiology · 2025Article
- Minimal Impact of COVID-19 on One-Year Mortality on US Patients with Cancer Diagnosed Early during the Pandemic.Cancer research communications · 2025Article
- Article
- Inequalities in relative cancer survival by race, immigration status, income, and education for 22 cancer sites in Canada, a cohort study.International journal of cancer · 2025Article
183 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate estimates of cancer survival are important for assessing optimal patient care and prognosis. Evaluation of these estimates via relative survival (a ratio of observed and expected survival rates) requires a population life table that is matched to the cancer population by age, sex, race and/or ethnicity, socioeconomic status, and ideally risk factors for the cancer under examination. Because life tables for all subgroups in a study may be unavailable, we investigated whether cause-specific survival could be used as an alternative for relative survival.
methodsWe used data from the Surveillance, Epidemiology, and End Results Program for 2,330,905 cancer patients from January 1, 1992, through December 31, 2004. We defined cancer-specific deaths according to the following variables: cause of death, only one tumor or the first of multiple tumors, site of the original cancer diagnosis, and comorbidities. Estimates of relative survival and cause-specific survival that were derived by use of an actuarial method were compared.
resultsAmong breast cancer patients who were white, black, or of Asian or Pacific Islander descent and who were older than 65 years, estimates of 5-year relative survival (107.5%, 106.6%, and 103.0%, respectively) were higher than estimates of 5-year cause-specific survival (98.6%, 95% confidence interval [CI] = 98.4% to 98.8%; 97.4%, 95% CI = 96.2% to 98.2%; and 99.2%, 95% CI = 98.4%, 99.6%, respectively). Relative survival methods likely underestimated rates for cancers of the oral cavity and pharynx (eg, for white cancer patients aged ≥65 years, relative survival = 54.2%, 95% CI = 53.1% to 55.3%, and cause-specific survival = 60.1%, 95% CI = 59.1% to 60.9%) and the lung and bronchus (eg, for black cancer patients aged ≥65 years, relative survival = 10.5%, 95% CI = 9.9% to 11.2%, and cause-specific survival = 11.9%, 95% CI = 11.2 % to 12.6%), largely because of mismatches between the population with these diseases and the population used to derive the life table. Socioeconomic differences between groups with low and high status in relative survival estimates appeared to be inflated (eg, corpus and uterus socioeconomic status gradient was 13.3% by relative survival methods and 8.8% by cause-specific survival methods).
conclusionAlthough accuracy of the cause of death on a death certificate can be problematic for cause-specific survival estimates, cause-specific survival methods may be an alternative to relative survival methods when suitable life tables are not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.